Letter to the Editor for ‘Neutrophil-To-Lymphocyte Ratio as a Marker in Patients With Non-Arteritic Anterior Ischemic Optic Neuropathy’

Balkan Medical Journal - Turkey
doi 10.5152/balkanmedj.2016.16063
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Galenos Yayinevi

Related search

Cataract Surgery and Non-Arteritic Anterior Ischemic Optic Neuropathy

Turkiye Klinikleri Journal of Ophthalmology
2016English

Delayed Non-Arteritic Anterior Ischemic Optic Neuropathy Following Acute Primary Angle Closure

Korean journal of ophthalmology : KJO
Medicine
2015English

Progression of Asymptomatic Optic Disc Swelling to Non-Arteritic Anterior Ischaemic Optic Neuropathy

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2016English

Comparison of Optic Nerve Head Morphology in Patients With Primary Open Angle Glaucoma and Non-Arteritic Anterior Ischemic Optic Neuropathy

Acta Clinica Croatica
Medicine
2017English

Atrial Fibrillation in Retinal Vascular Occlusion Disease and Non-Arteritic Anterior Ischemic Optic Neuropathy

PLoS ONE
Multidisciplinary
2017English

The Evaluation of Neutrophil-To-Lymphocyte Ratio as a Novel Marker in Patients With Pterygium

Turkiye Klinikleri Journal of Ophthalmology
2020English

Response to the Letter to the Editor “The Relationship Between Neutrophil–Lymphocyte Ratio and In-Stent Restenosis”

Angiology
Cardiovascular MedicineCardiology
2018English

Neutrophil-To-Lymphocyte Ratio as an Early Marker of Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Nivolumab

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2018English

Role of Aspirin in Reducing the Frequency of Second Eye Involvement in Patients With Non-Arteritic Anterior Ischaemic Optic Neuropathy

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy